Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (671)	9/7/1999 10:20:00 AM
From: BRAVEHEART	Respond to of 1494

Ear Level, John I for one hope our enthusiasms are indeed met. It is difficult at best to come up with investments which have considerable potential and are well managed from an operating perspective. Yes NTI is fortunate to have the negotiating acumen of a Paul Frieman & the leverage of MERZ in negotiating with big Pharma. Yes we are dependant on clinical results. But I would surmise the likelihood of selling out early is very low. That along with the low dilution will translate directly to us the shareholder as these upcoming significant milestones are met. The truth is John your posts are music to my ears. Mostly because you post endlessly & factually on a "low volume issue". This clearly is not the makings of a hype story. With positive clinicals & a collaboration the markets will react. There is no question about that. With or without the hype. Best Wishes Jeffrey